SNY Down Despite Eczema Candidate Meeting Goal in Phase III Study

Sanofi's amlitelimab met all primary and key secondary endpoints in its Phase III COAST 1 study for moderate-to-severe atopic dermatitis, demonstrating statistically significant efficacy and a potential differentiated quarterly dosing regimen. Despite these positive clinical results, Sanofi shares declined 8.8% in pre-market trading as analysts expressed concerns that amlitelimab's efficacy fell short of investor expectations, particularly when compared to the company's existing blockbuster drug, Dupixent.

Analysis

Sanofi announced that its eczema candidate, amlitelimab, successfully met all primary and key secondary endpoints in its Phase III COAST 1 study, demonstrating statistically significant efficacy and a favorable safety profile. However, this positive clinical outcome was met with a significant negative market reaction, as Sanofi's shares (SNY) fell 8.8% in pre-market trading. This decline stems from investor sentiment that amlitelimab's effectiveness, based on the initial data, falls short when compared to Sanofi's own blockbuster drug, Dupixent, which it co-develops with Regeneron. Dupixent is a commercial juggernaut, having generated €7.31 billion in sales in the first half of 2025, a 20.7% year-over-year increase, and dominates the market for atopic dermatitis. Management has highlighted amlitelimab's key potential differentiator: a less frequent dosing schedule of just four times per year. The ultimate commercial viability of amlitelimab now hinges on further data from four other Phase III studies, expected through 2026, which will provide a more comprehensive view of its long-term efficacy and determine if its convenience advantage can carve out a meaningful share against the high bar set by Dupixent.

Key Decisions for Investors

• Investors should view the 8.8% stock decline as a market pricing in the risk that amlitelimab's efficacy may be inferior to Dupixent, creating a potential entry point for those bullish on the drug's convenience-driven, long-term commercial prospects.
• Monitor the full data releases from the OCEANA clinical program through 2026, as the key determinant of value will be whether amlitelimab's quarterly dosing advantage can meaningfully compete with Dupixent's established efficacy profile.
• Given the high bar set by Dupixent, any further clinical data suggesting amlitelimab is not best-in-class will likely result in continued pressure on Sanofi's valuation, making upcoming trial results a critical catalyst to watch.